SINTETICA acquired by ARDIAN
Context
Ardian acquired a majority stake in Sintetica from the majority shareholder Daphne and the owner family. The transaction was structured as a partnership, with the existing shareholders and management team reinvesting via a significant minority stake to maintain continuity. At the time of the deal, Sintetica was in a phase of hyper-growth (31% CAGR between 2016-2018). Ardian's investment was designed to accelerate the company's internationalization—expanding its reach beyond the 45 countries it already served—and to fuel R&D for new patented, "ready-to-use" drug delivery systems that optimize hospital efficiency and patient safety.
SINTETICA, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Sintetica is a long-standing Swiss pharmaceutical company specializing in the research, manufacturing, and marketing of high-quality sterile injectable solutions. Its portfolio focuses on innovative "ready-to-use" formulations for local anesthesia and pain management, specifically designed to reduce opioid reliance and support the global trend of ambulatory (one-day) surgery.
Ent. Value
CHF 50–100M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (CHF)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2019 | PERMIRA | QUOTIENT SCIENCES | UNITED KINGDOM | CDMO |
| 07/2019 | 3I | IONISOS | FRANCE | CDMO |
| 04/2019 | EURAZEO | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 04/2019 | ICG / MERIEUX EQUITY PARTNERS | DOC GENERICI | ITALY | Generics / Labs |
| 12/2018 | MERCK & CO. | ANTELLIQ | FRANCE | Animal Health |
| 11/2018 | ARDIAN | NEOPHARMED GENTILI | ITALY | Generics / Labs |
| 10/2018 | BRIDGEPOINT | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 10/2018 | GLANBIA | SLIMFAST | UNITED STATES | Nutrition & Dietary Supplements |
| 10/2018 | ASTORG | NEMERA | FRANCE | Medical Consumables |
| 10/2018 | ARDIAN | INULA GROUP | BELGIUM | Pharma & Biotech |
Other operations with ARDIAN
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | ARDIAN / EURAZEO / UBS | HR PATH | FRANCE | ERP, HR & Finance |
| 07/2026 | ARDIAN | Munich Electrification | GERMANY | Batteries & EV Tech |
| 07/2026 | ARDIAN | Pflegia | GERMANY | Recruitment / Headhunting |
| 01/2026 | ARDIAN | IVB Wellness Lab | SPAIN | Nutrition & Dietary Supplements |
| 12/2025 | ARDIAN | Fermax | SPAIN | Safety & Security |
| 07/2025 | ARDIAN | Dovida | SWITZERLAND | Outpatient Care |
| 05/2025 | ARDIAN | MasterGrid | FRANCE | Electrical |
| 03/2025 | ARDIAN | DIOT-SIACI | FRANCE | Brokerage |
| 03/2025 | ARDIAN | AKUO | FRANCE | Renewables |
| 01/2025 | ARDIAN / EURAZEO / ASTORG | SYCLEF | FRANCE | HVAC (Heating/AC) |
REFERENCES
Revenue range: CHF 50–100M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SINTETICA by ARDIAN are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: ardian